Melasmahttps://en.wikipedia.org/wiki/Melasma
Is éard atá i Melasma dath dath donn nó dath dorcha d’aghaidh. Ceaptar gur nochtadh na gréine, réamhshuíomh géiniteach, athruithe hormóin agus greannú craicinn is cúis le melasma. Cé go bhféadfadh sé difear a dhéanamh do dhuine ar bith, tá sé coitianta go háirithe i mná, go háirithe mná torracha agus iad siúd atá ag glacadh frithghiniúnach nó míochainí teiripe athsholáthair hormóin.

Ní féidir melasma a réiteach le cóireáil léasair ar feadh tréimhse áirithe ama, toisc gur galar é ina dtáirgtear lí go leanúnach. Cuidíonn aigéad tranxenemic chun feabhas a chur ar laghdú ar an pigmentation.

Cóireáil
I roinnt tíortha (m.sh. an tSeapáin, an Chóiré), tá aigéad tranexamic béil ar fáil thar an gcuntar agus tá sé éifeachtach. D'fhéadfadh go mbeadh an uachtar melasma le haigéad tranexamic agus aigéad azelaic ina chuidiú go páirteach.
Féadfar hidroquinone a úsáid go topach chun hipearpigmentation a chóireáil, ach chuir an FDA stop leis na táirgí thar an gcuntar a raibh hidreacuineon iontu ó 2020.
#Tranexamic acid [TRANSINO]

#Laser toning technique (low fluence QS1064 laser)
#Triluma
☆ I dtorthaí 2022 Stiftung Warentest ón nGearmáin, ní raibh sástacht na dtomhaltóirí le ModelDerm ach beagán níos ísle ná mar a bhí le comhairliúchán teileamhíochaine íoctha.
  • Is coinníoll coitianta é a breathnaíodh i mná na hÁise sna 40idí luatha. Tá an lot ciorclach sa ghrianghraf níos gaire do lentigo seachas melasma.
    References Efficacy and Safety of Tranexamic Acid in Melasma: A Meta-analysis and Systematic Review 28374042
    Tranexamic acid is a novel treatment option for melasma; however, there is no consensus on its use. This systematic review searched major databases for relevant publications to March 2016. Eleven studies with 667 participants were included. Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI after treat?ment with tranexamic acid. The addition of tranexamic acid to routine treatment modalities resulted in a further decrease in MASI of 0.94. These results support the efficacy and safety of tranexamic acid, either alone or as an adjuvant to routine treatment modalities for melasma.
     The Low-Fluence Q-Switched Nd:YAG Laser Treatment for Melasma: A Systematic Review 35888655 
    NIH
    Le déanaí, tá tóir ar léasair low-fluence Q-switched Nd:YAG (LFQSNY) chun melasma a chóireáil, go háirithe san Áise. Bhí sé dúshlánach staidéir éagsúla a achoimriú, ach is cosúil go ginearálta go bhfuil LFQSNY éifeachtach agus sábháilte le haghaidh melasma i gcomparáid le teiripí traidisiúnta. Mar sin féin, tuairiscíodh roinnt cásanna de hypopigmentation mottled mar fo-éifeacht LFQSNY, b'fhéidir mar gheall ar fhuinneamh léasair ard. Is féidir hyperpigmentation ó athlasadh a bheith mar thoradh ar úsáid ionsaitheach LFQSNY, go háirithe i toin dorcha craiceann.
    Recently, the low-fluence Q-switched Nd:YAG laser (LFQSNY) has been widely used for treating melasma, especially in Asia. It was hard to summarize the heterogenous studies, but LFQSNY appeared to be a generally effective and safe treatment for melasma considering the results of previous conventional therapies. However, mottled hypopigmentation has been occasionally reported to develop and persist as an adverse event of LFQSNY, which may be associated with the high accumulated laser energy. When used aggressively, even LFQSNY can induce hyperpigmentation via unwanted inflammation, especially in darker skin.
     Pigmentation Disorders: Diagnosis and Management 29431372
    Is minic a aimsítear fadhbanna líocha i gcúram príomhúil. I measc na gcineálacha coitianta neamhoird hyperpigmentation tá post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.
    Pigmentation problems are often found in primary care. Common types of hyperpigmentation disorders include post-inflammatory hyperpigmentation, melasma, sunspots, freckles, café au lait spots.